Magic mushroom compound tested for IBS relief

NCT ID NCT06206265

Ongoing Symptom relief Sponsor: TRYP Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This small pilot study is testing whether psilocybin (the active ingredient in magic mushrooms) given alongside psychotherapy can safely help adults with irritable bowel syndrome (IBS). Fourteen participants will receive two doses of 25 mg of psilocybin in a controlled setting. The study uses a delayed-start design, meaning some people get treatment right away while others wait, to compare effects. The main focus is on safety, but researchers will also track changes in pain, stool habits, and mood.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: psilocybin (TRP-8802)
What this could lead to: If it works, this could point toward a new treatment option for irritable bowel syndrome that combines a psychedelic drug with talk therapy.
What could go wrong: This is a very small, early-phase pilot study with only 14 people. It is designed mainly to test safety, not effectiveness, so results may not apply broadly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IRRITABLE BOWEL SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

irritable bowel syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IRRITABLE BOWEL SYNDROME

Contacts and locations

Locations

Massachusetts General Hospital

Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.